Navigation Links
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. -- AMAG
Date:9/25/2013

NEW YORK, Sept. 25, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company")(NASDAQ: AMAG).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.

The investigation concerns whether AMAG and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.  On December 21, 2012, AMAG submitted to the U.S. Food and Drug Administration (the "FDA") a supplemental New Drug Application (the "sNDA") under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Feraheme (ferumoxytol) Injection, 510 mg. The sNDA sought approval for a broader indication for Feraheme for the treatment of iron deficiency anemia in adult patients who have failed or could not use oral iron. On September 23, 2013, the Company received a notification from the FDA stating that, as part of its ongoing review of the Company's sNDA, the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments by September 23, 2013, a target date previously communicated by the FDA in a letter dated March 5, 2013.  On September 25, 2013 the Company announced in an Securities and Exchange Commission Form 8-K filing, information regarding the FDA notification received on September 23, 2013.

On this news, shares of AMAG fell $3.09 per share to more than 11.81% on intraday trading to a price of  $23.07 on September 25, 2013.

The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz Grossman Hufford Dahlstrom & Gross LLP
rswilloughby@pomlaw.com


'/>"/>
SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. China Nepstar Chain Drugstore Schedules Annual General Meeting of Shareholders for October 25, 2013
2. SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Astex Pharmaceuticals, Inc.
3. Buyout Alert -- Astex Pharmaceuticals -- Law Firm Seeks Higher Price For Shareholders
4. Hi Tech Shareholder Alert - Buyout Of Hi Tech - Law Firm Seeks Higher Price For Shareholders
5. Shareholder Alert: Pomerantz Law Firm has filed a Class Action Against Biolase, Inc. and Certain Officers - BIOL
6. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
7. Concord Medical Announces Acquisition of Its Shares by CEO and COO from Other Shareholders
8. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
9. FDA Approvals, Dividends, New Technologies, and Solid Margins Increase Shareholder Value - Research Report on Abbott, Baxter, CareFusion, Haemonetics, and CR Bard
10. Teamsters Protest McKessons Worker Abuse And Executive Pay At Shareholder Meeting
11. Alliquas CEO Issues Midyear Corporate Update for Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... , July 5, 2017 ... www.oramed.com ), a clinical-stage pharmaceutical company focused ... that it has received approval from the Israel Securities Authority ... Exchange (TASE). Oramed common stock will commence trading on the ... on the current market capitalization of the Company, it is ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade cell ... freeze media ("BioLife"), today announced that it has ... debt holder and largest shareholder, to modify its existing ... Pursuant to the modification, WAVI agreed to exchange its ...
(Date:6/30/2017)... 30, 2017 In vitro diagnostics market firm ... May, at least ten diagnostic companies have successfully completed ... offerings and a loan facility.  The size of these ... million.  Kalorama Information provides a monthly IVD Market ... Knowledge Center. ...
Breaking Medicine Technology:
(Date:7/21/2017)... , ... July 21, 2017 , ... “Kids aren't born ... to tie their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company ... which launches on Kickstarter on Monday, July 21st. , The kit uses colorful, ...
(Date:7/21/2017)... ... 21, 2017 , ... The most common surgical techniques used ... life five years after injury, according to research presented today at the ... The study followed patients for five years following surgery. , “Orthopaedic surgeons have ...
(Date:7/20/2017)... ... 2017 , ... Acute myeloid leukemia (AML) is a rare ... treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem cell transplant ... such a challenging diagnosis that requires immediate action, patients and caregivers need accessible ...
(Date:7/20/2017)... Melville, New York (PRWEB) , ... July 20, ... ... it has developed a telemedicine platform, in which their iMedSecure™ comes included with ... Solutions both share encrypted live images to remote participants for real-time collaboration and ...
(Date:7/20/2017)... ... ... Girl Up Campaign Director, Melissa Kilby, released the statement ... providing girls access to education in refugee settings. In May, Congressman Steve Chabot (R-OH) ... Education in Vulnerable Settings Act.” Yesterday, companion legislation was introduced in the Senate ...
Breaking Medicine News(10 mins):